when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

OTSUKA · news · pharmadog

← back to OTSUKA

News mentioning OTSUKA

52 stories

19dEstuary flows out of stealth with $103M to propel kidney disease gene therapies into clinicfiercebiotech

26dOn the move: 4 rare disease companies hiring nowbiospace

Sep 24, 26Lilly’s latest China drug deal; Immunovant’s setback in lupusbiopharma dive

Sep 23, 26Roche, Ionis RNA drug scores in kidney disease studybiopharma dive

Sep 23, 26Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodbiospace

Sep 23, 26Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSbiospace

Sep 23, 26Roche kidney drug's Phase 3 win sets up path to accelerated approvalendpoints

Sep 22, 26Vertex opens up larger kidney disease opportunity with mid-stage readoutbiospace

Sep 22, 26Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand dealendpoints

Sep 22, 26STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge programstat

Sep 22, 26Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpointfiercebiotech

Sep 21, 26How J&J paved the way for Compass’ coming psychedelic drug launchbiopharma dive

Sep 21, 26Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injectionfda medwatch

Sep 16, 26Deep dive: Psychedelics back on FDA’s doorstepbiospace

Sep 16, 265 biotechs braving the commercial waters with product launchesbiospace

Sep 14, 26Psychedelic therapies ride wave of public favor into FDA hearingbiospace

Sep 3, 26Psilocybin proves promising in neuropathic pain mouse studyfiercebiotech

Aug 20, 26Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialendpoints

Aug 17, 26Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxactbiospace

Aug 13, 26Meet Motivista: Click Therapeutics debuts first-of-its-kind schizophrenia digital therapeuticfiercebiotech

Aug 12, 26Boulevard starts up with $65M to pursue targeted autoimmune drugsbiopharma dive

Aug 4, 26Otsuka succeeds with kidney drug; BioNTech downgrades revenue projectionendpoints

Aug 4, 26Vertex unfazed by competitive IgAN space as FDA verdict loomsbiospace

Jul 28, 26Eli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

Jul 27, 26Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pillendpoints

Jul 27, 26FDA scientists question Capricor data; Legend CEO steps downbiopharma dive

Jul 27, 26Otsuka’s ADHD approval opens up new drug class with $615M opportunitybiospace

Jul 24, 26Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesbiospace

Jul 20, 26Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsbiospace

Jul 18, 26‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsfiercebiotech

← prevpage 1 of 2next →